학술논문
Efficacy and safety of the novel capsid inhibitor lenacapavir to treat multidrug-resistant HIV: week 52 results of a phase 2/3 trial
Document Type
Article
Author
Ogbuagu, Onyema; Segal-Maurer, Sorana; Ratanasuwan, Winai; Avihingsanon, Anchalee; Brinson, Cynthia; Workowski, Kimberly; Antinori, Andrea; Yazdanpanah, Yazdan; Trottier, Benoit; Wang, Hui; Margot, Nicolas; Dvory-Sobol, Hadas; Rhee, Martin S; Baeten, Jared M; Molina, Jean-Michel; DeJesus, Edwin; Richmond, Gary J.; Berhe, Mezgebe; Ruane, Peter J.; Sinclair, Gary Ian; Lichtenstein, Kenneth; Ramgopal, Moti N.; Wiznia, Andrew; Workowski, Kimberly; Sanchez, William; Brinson, Cynthia; McGowan, Joseph P.; Creticos, Catherine M.; Berger, Daniel S.; Wheeler, David A.; Hagins, Debbie; Crofoot, Gordon E.; Sims, James; Osiyemi, Olayemi; Hodge, Theo; Zurawski, Christine; Ogbuagu, Onyema; Segal-Maurer, Sorana; Ratanasuwan, Winai; Avihingsanon, Anchalee; Siripassorn, Krittaecho; Chetchotisakd, Ploenchan; Castagna, Antonella; Antinori, Andrea; Castelli, Francesco; Ronot-Bregigeon, Sylvie; Molina, Jean-Michel; Yazdanpanah, Yazdan; Trottier, Benoit; Brunetta, Jason; Shirasaka, Takuma; Yokomaku, Yoshiyuki; Koenig, Ellen; Mallolas, Josep; Stellbrink, Hans-Jurgen; Hung, Chien-Ching; Rassool, Mohammed
Source
The Lancet HIV; August 2023, Vol. 10 Issue: 8 pe497-e505, 9p
Subject
Language
ISSN
24054704; 23523018
Abstract
Lenacapavir, a first-in-class HIV-1 capsid inhibitor, is in development as a long-acting agent for treating and preventing HIV-1. We aimed to evaluate the efficacy and safety of lenacapavir with an optimised background regimen in adults living with multidrug-resistant HIV-1 up to 52 weeks.